Takeda halts development of prostate cancer drug
- Takeda has stopped development of orteronel (TAK-700) for prostate cancer.
- Takeda’s decision was driven by phase III data showing no overall survival benefit compared with other therapies.
- Orteronel was being developed for treatment of men with metastatic, castration resistant prostate cancer (mCRPC) .
In one of the phase III trials that led to the decision to halt development of orteronel, the combination of orteronel and prednisone improved progression-free survival, but did not significantly increase overall survival. Given the current emphasis on value-based treatments and decision-making based on evidence, it makes sense that Takeda would choose to halt the trial.
Takeda has contacted clinical trial investigators and is supporting their efforts to help patients transition to other therapies.